Cargando…
Sotorasib: First Approval
Sotorasib (LUMAKRAS(™)) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adu...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531079/ https://www.ncbi.nlm.nih.gov/pubmed/34357500 http://dx.doi.org/10.1007/s40265-021-01574-2 |